Table of Content - Minimal Residual Disease Testing Market

The global minimal residual disease testing market is estimated to be valued at USD 2.31 Bn in 2024 and is expected to exhibit a CAGR of 11.6% during the forecast period (2024-2031). Minimal Residual Disease (MRD) testing involves detecting tiny amounts of residual cancer cells that may remain in the body after initial treatment. It is an important tool for both hematologists and oncologists to monitor treatment response and predict outcomes for patients. MRD testing allows physicians to identify those who may be at higher risk of disease relapse earlier than other methods. This helps determine if additional therapies or closer monitoring is needed. Several technologies such as multiparameter flow cytometry, allele-specific oligonucleotide quantitative PCR, and next generation sequencing are used to detect MRD with high sensitivity. With growing applications of MRD testing across different types of blood cancers and improving technologies, the market is expected to witness significant growth in the coming years.

Market Dynamics:

The global minimal residual disease testing market is driven by rising incidence of hematological cancers, increasing adoption of MRD testing in treatment monitoring, and growing awareness among physicians. However, lack of skilled professionals, high index of testing methods, and reimbursement issues in some regions are restraining the market growth. Various new product launches by players with improved sensitivity and automated platforms present key opportunities. For instance, personalized therapy and liquid biopsy techniques are emerging areas. Collaborations between companies and research institutes are also supporting market expansion into new geographies. The effects of the COVID-19 pandemic on healthcare resources is a challenge, though telemedicine and home-based sample collection aid continuity of MRD monitoring in current scenario.

Key Features of the Study:

This report provides an in-depth analysis of the global minimal residual disease testing market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global minimal residual disease testing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global minimal residual disease testing market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global minimal residual disease testing market

Detailed Segmentation-

Technology:
- Flow Cytometry
- Polymerase chain reaction (PCR)
- Next generation sequencing
Application:
- Lymphoma
- Solid Tumors
- Others
End User:
- Hospitals
- Clinics
- Research Laboratories
- Others
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Bio-Rad Laboratories, Inc.
- Hoffmann-La Roche Ltd
- Guardant Health, Inc.
- Adaptive Biotechnologies
- Invitae Corporation
- ASURAGEN, INC.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Natera, Inc.
- Sysmex Inostics, Inc.
- Amgen Inc.
- FOUNDATION MEDICINE, INC.
- Sebia
- Myriad Genetics, Inc.

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Technology
  - Market Snapshot, By Application
  - Market Snapshot, By End User
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Impact Analysis
- Market Trends
- Epidemiology
- Recent Developments
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter’s Analysis
Global Minimal Residual Disease Testing Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
Global Minimal Residual Disease Testing Market, By Technology, 2019 – 2031, (USD Bn)
- Overview
  - Market Share Analysis, 2024 and 2031 (%)
  - Y-o-Y Growth Analysis, 2020 – 2031
  - Segment Trends
- Flow Cytometry
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
- Polymerase chain reaction (PCR)
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
- Others
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
Global Minimal Residual Disease Testing Market, By Application, 2019 – 2031, (USD Bn)
- Overview
  - Market Share Analysis, 2024 and 2031 (%)
  - Y-o-Y Growth Analysis, 2020 – 2031
  - Segment Trends
- Lymphoma
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
- Solid Tumors
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
- Others
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
Global Minimal Residual Disease Testing Market, By End User, 2019 – 2031, (USD Bn)
- Overview
  - Market Share Analysis, 2024 and 2031 (%)
  - Y-o-Y Growth Analysis, 2020 – 2031
  - Segment Trends
- Hospitals
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
- Clinics
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
- Research Laboratories
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
- Others
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
Global Minimal Residual Disease Testing Market, By Region, 2019 – 2031, (USD Bn)
- Introduction
  - Market Share Analysis, By Region, 2024 and 2031 (%)
  - Y-o-Y Growth Analysis, For Regions, 2020–2031
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD Bn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD Bn)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD Bn)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD Bn)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD Bn)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 – 2031, (USD Bn)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Company Profiles
  - Bio-Rad Laboratories, Inc.*
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - F. Hoffmann-La Roche Ltd
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Guardant Health, Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Adaptive Biotechnologies
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Invitae Corporation
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - ASURAGEN, INC.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Invivoscribe, Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Laboratory Corporation of America Holdings
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Natera, Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Sysmex Inostics, Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Amgen Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - FOUNDATION MEDICINE, INC.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Sebia
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
  - Myriad Genetics, Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Market Strategies
Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact

*Browse 32 market data tables and 30 figures on “Minimal Residual Disease Testing Market” - Global forecast to 2031

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now